Several top-performing testosterone replacement therapies will be losing their patents in the next few years, opening the door for less expensive generics and cutting into brand-name drug profits, according to a study conducted by Transparency Market Research. The study divided testosterone treatments into specific types – topical creams and gels, transdermal patches, injections, gum/buccal adhesives, implants, and oral drug forms. Creams and gels led the global market, particularly brands such as AndroGel by AbbVie, Axiron from Eli Lilly and Company, and Testim by Endo Pharmaceuticals. The creams and gels soared in sales in part because consumers found them easier to ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.